Prevalence of EGFR Gene Fusions in a Large Cohort of Chinese Patients with Non-Small Cell Lung Cancer (NSCLC).
Chunwei Xu,Wen Xian Wang,Yu Chen,You-cai Zhu,Yueping Liu,Hong Wang,Wu Zhuang,Xiaohui Chen,Yun-jian Huang,Jinhuo Lai,Meiyu Fang,Zhenghua Zhang,Ye Tao,Shuguang Xu,Xue Qian,Hongyu Zhao,Jing Ma,Gang Chen,Tangfeng Lv,Yong Song
DOI: https://doi.org/10.1200/jco.2018.36.15_suppl.e13538
IF: 45.3
2018-01-01
Journal of Clinical Oncology
Abstract:e13538 Background: Currently, with the advances in detection techniques, such as next generation sequencing (NGS), more and more rare or atypical EGFR mutations had been identified. Such as exons 18-25 kinase domain duplications (KDD) and EGFR fusions (EGFR-RAD51 or EGFR-PURB), the importance of EGFR signaling in the pathogenesis of lung cancer and the efficacy of EGFR-TKI treatment had been demonstrated. The aim of this study was to evaluate the prevalence of EGFR fusions in Chinese NSCLC patients, and to study the association between these molecular alterations and clinicopathological characteristics in these patients. Methods: A multicenter study in China was initiated from February 2014, and NSCLC patients have been enrolled as of December 2017. A total of 2410 patients with NSCLC (non-squamous/squamous =2061/349) were screened by using next-generation sequencing (NGS)-based 381 genes panel assay for detecting EGFR fusions. Results: Of this entire cohort, just two (0.08%) patients were identified with an EGFR-SEPT14 fusion and an EGFR-RAD51 fusion. These two patients was that a 62-year-old never smoking female, who was diagnosed with lung adenocarcinoma and a 48-year-old male with a 32 pack-year smoking history, who was diagnosed with lung adenocarcinoma. The first patient: EGFR-SEPT14 fusion driven NSCLC responding to icotinib, there were no treatment-related adverse events, including abnormal hepatic, renal function, gastrointestinal reactions, rashes, and cordis damage. Thus far, after several months, the disease is stable and she is continuing treatment with icotinib; The second patient: EGFR-RAD51 fusion driven NSCLC responding to erlotinib will be presented. The patient was considered to have a partial response (PR) to erlotinib. During treatment with erlotinib, no abnormal hepatic and renal function occurred. Conclusions: The frequency of EGFR fusions in Chinese patients with NSCLC is extremely rare (0.08%). The NGS assay provides a novel diagnostic tool. In the future, we can explore differences in the acquired mechanism underlying EGFR TKIs between sensitive EGFR mutations and other uncommon variant NSCLC patients.